In vitro activity of dalbavancin against Gram-positive bacteria isolated from diabetic foot osteomyelitis.

Alix PantelOriane NacharAgathe BoudetPaul LoubetSophie SchuldinerNicolas CellierAlbert SottoCatherine Dunyach-RemyJean-Philippe Lavigne

Published in: The Journal of antimicrobial chemotherapy (2021)

With its efficacy, good tolerability and unique pharmacokinetic properties, dalbavancin appears to be a promising treatment for DFOM involving Gram-positive bacteria.

Keyphrases

gram negative
multidrug resistant
open label
randomized controlled trial
clinical trial
combination therapy
double blind